X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1619) 1619
Publication (97) 97
Newsletter (36) 36
Book Review (25) 25
Newspaper Article (10) 10
Book Chapter (5) 5
Magazine Article (5) 5
Conference Proceeding (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
darbepoetin alfa (1226) 1226
humans (1192) 1192
erythropoietin - analogs & derivatives (924) 924
anemia (721) 721
anemia - drug therapy (697) 697
male (690) 690
erythropoietin - therapeutic use (685) 685
index medicus (655) 655
female (636) 636
middle aged (490) 490
hematinics - therapeutic use (479) 479
aged (458) 458
erythropoietin (453) 453
erythropoietin - administration & dosage (432) 432
recombinant proteins (419) 419
recombinant-human-erythropoietin (418) 418
anemia - etiology (407) 407
epoetin alfa (350) 350
treatment outcome (304) 304
urology & nephrology (302) 302
darbepoetin-alpha (296) 296
adult (269) 269
hematinics - administration & dosage (267) 267
hemoglobin (253) 253
epoetin-alpha (251) 251
erythropoietin - adverse effects (246) 246
quality-of-life (246) 246
double-blind (239) 239
oncology (228) 228
chronic kidney-disease (217) 217
pharmacology & pharmacy (211) 211
cancer (199) 199
drug administration schedule (197) 197
kidney failure, chronic - complications (179) 179
hematinics - adverse effects (178) 178
hemoglobins - metabolism (177) 177
animals (176) 176
aged, 80 and over (175) 175
chronic kidney disease (173) 173
anemia - chemically induced (171) 171
hemoglobins - analysis (169) 169
neoplasms - drug therapy (167) 167
renal dialysis (167) 167
quality of life (165) 165
anaemia (163) 163
anemia - blood (160) 160
chemotherapy (158) 158
dose-response relationship, drug (157) 157
antineoplastic agents - adverse effects (156) 156
care and treatment (154) 154
darbepoetin alpha (149) 149
trial (145) 145
erythropoietin - pharmacology (142) 142
hematology (139) 139
neoplasms - complications (139) 139
mortality (137) 137
drug therapy (134) 134
medicine & public health (134) 134
hemodialysis (133) 133
prospective studies (130) 130
hemodialysis-patients (129) 129
retrospective studies (126) 126
risk factors (125) 125
darbepoetin (123) 123
medicine, general & internal (122) 122
erythropoiesis-stimulating agents (120) 120
research (114) 114
kidney failure, chronic - therapy (110) 110
epoetin (109) 109
time factors (108) 108
dialysis (101) 101
analysis (100) 100
erythropoiesis - drug effects (100) 100
chronic kidney failure (99) 99
dialysis patients (96) 96
kidney diseases (96) 96
randomized controlled trials as topic (96) 96
injections, subcutaneous (95) 95
therapy (94) 94
erythropoietin, recombinant (93) 93
placebo-controlled trial (93) 93
cardiac & cardiovascular systems (92) 92
health aspects (90) 90
pharmacokinetics (90) 90
anemia - complications (89) 89
cancer-patients (88) 88
chemotherapy-induced anemia (88) 88
erythropoietin - economics (88) 88
dosage and administration (86) 86
nephrology (86) 86
medicine, research & experimental (85) 85
renal insufficiency, chronic - complications (83) 83
erythropoiesis (80) 80
erythropoietin - pharmacokinetics (80) 80
internal medicine (80) 80
iron (80) 80
chronic disease (77) 77
injections, intravenous (75) 75
complications and side effects (74) 74
transplantation (74) 74
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1557) 1557
Spanish (38) 38
French (28) 28
German (19) 19
Japanese (7) 7
Polish (7) 7
Italian (5) 5
Korean (5) 5
Hungarian (3) 3
Czech (2) 2
Russian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2007, Volume 49, Issue 7, pp. 753 - 762
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2013, Volume 368, Issue 13, pp. 1210 - 1219
In this trial, patients with systolic heart failure and anemia were assigned to receive either darbepoetin alfa or placebo. At 28 months, there was no... 
MORTALITY | CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | CITY CARDIOMYOPATHY QUESTIONNAIRE | EPOETIN | MORBIDITY | REDUCTION | DOUBLE-BLIND | CHRONIC KIDNEY-DISEASE | Shock, Septic - etiology | Double-Blind Method | Heart Failure, Systolic - drug therapy | Hematinics - therapeutic use | Erythropoietin - therapeutic use | Heart Failure, Systolic - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Erythropoietin - adverse effects | Hematinics - adverse effects | Male | Thromboembolism - etiology | Erythropoietin - analogs & derivatives | Stroke - etiology | Anemia - drug therapy | Treatment Failure | Female | Aged | Darbepoetin alfa | Anemia - etiology | Hemoglobins - analysis | Heart Failure, Systolic - complications | Heart failure | Usage | Care and treatment | Anemia | Patient outcomes | Diagnosis | Clinical trials | Patient safety | Hemoglobin | Thromboembolism | Patients | Heart diseases | Cancer | Shock | Systolic/mortality | Hematinics/adverse effects | chronic heart failure | Erythropoietin/analogs & derivatives | Thromboembolism/etiology | Klinisk medicin | Heart Failure | Anemia/drug therapy | Hematinics/therapeutic use | Erythropoietin/therapeutic use | Hemoglobins/analysis | Anemia/etiology | Erythropoietin/adverse effects | Stroke/etiology | Clinical Medicine | Systolic/complications | Septic/etiology | Systolic/drug therapy
Journal Article
Circulation, ISSN 0009-7322, 12/2011, Volume 124, Issue 25, pp. 2903 - 2908
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2015, Volume 66, Issue 1, pp. 106 - 113
Background Adequately powered studies directly comparing hard clinical outcomes of darbepoetin alfa (DPO) versus epoetin alfa (EPO) in patients undergoing... 
Nephrology | erythropoiesis-stimulating agent (ESA) | darbepoetin alfa (DPO) | epoetin alfa (EPO) | Mortality | safety | myocardial infarction | hemodialysis | renal replacement therapy (RRT) | cardiovascular | stroke | recombinant erythropoietin | PEGINESATIDE | TRIAL | ENDOTHELIAL PROGENITOR CELLS | DISEASES | DIALYSIS PATIENTS | UROLOGY & NEPHROLOGY | ERYTHROPOIESIS STIMULATING PROTEIN | ANEMIA | TREAT | Kidney Failure, Chronic - mortality | Recombinant Proteins - therapeutic use | United States - epidemiology | Myocardial Infarction - epidemiology | Erythropoietin - therapeutic use | Humans | Middle Aged | Erythropoietin - adverse effects | Male | Renal Insufficiency, Chronic - complications | Cause of Death | Erythropoietin - analogs & derivatives | Anemia - drug therapy | Cardiovascular Diseases - mortality | Renal Insufficiency, Chronic - mortality | Female | Registries | Stroke - epidemiology | Retrospective Studies | Epoetin Alfa | Anemia - etiology | Hematinics - therapeutic use | Comorbidity | Proportional Hazards Models | Treatment Outcome | Erythropoietin - pharmacokinetics | Hemodialysis Units, Hospital | Kidney Failure, Chronic - therapy | Kidney Failure, Chronic - complications | Ambulatory Care Facilities | Aged | Darbepoetin alfa | Renal Dialysis | Myocardial Infarction | Stroke | Cardiovascular | Safety
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2011, Volume 22, Issue 9, pp. 1988 - 1998
Background: Preoperative chemotherapy is a recommended treatment of both primary operable and locally advanced breast cancer. Strategies to improve efficacy... 
Neoadjuvant chemotherapy | Pathological complete response | Darbepoetin alfa | Primary breast cancer | Dose-dense chemotherapy | Dose-intensified chemotherapy | pathological complete response | primary breast cancer | COLONY-STIMULATING FACTOR | CYCLOPHOSPHAMIDE | PRIMARY SYSTEMIC TREATMENT | ADJUVANT TREATMENT | dose-intensified chemotherapy | EPOETIN-ALPHA | DOCETAXEL | COMPLETE ERADICATION | dose-dense chemotherapy | neoadjuvant chemotherapy | ONCOLOGY | INTERNATIONAL EXPERT PANEL | darbepoetin alfa | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Filgrastim | Dose-Response Relationship, Drug | Young Adult | Erythropoietin - analogs & derivatives | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Erythropoietin - administration & dosage | Polyethylene Glycols | Hemoglobins - metabolism | Paclitaxel - adverse effects | Breast Neoplasms - drug therapy | Preoperative Care | Recombinant Proteins - administration & dosage | Methotrexate - adverse effects | Breast Neoplasms - pathology | Breast Neoplasms - blood | Methotrexate - administration & dosage | Aged | Patient Compliance | Epirubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2009, Volume 361, Issue 21, pp. 2019 - 2032
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2016, Volume 38, Issue 1, pp. 122 - 135.e6
Abstract Purpose Limited data are available to describe the effectiveness of darbepoetin alfa (DA) in terms of hemoglobin (Hb) and transfusion outcomes when... 
Internal Medicine | Medical Education |